Inspire Medical Systems/$INSP

1D1W1MYTD1Y5YMAX

About Inspire Medical Systems

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
Ticker
$INSP
Sector
Health
Primary listing
NYSE
Employees
1,333
Headquarters
Golden Valley, United States
Website
www.inspiresleep.com

INSP Metrics

BasicAdvanced
$2.1B
15.79
$4.61
0.67
-

What the Analysts think about INSP

Analyst ratings (Buy, Hold, Sell) for Inspire Medical Systems stock.
Analyst projections of the future price of Inspire Medical Systems stock.

Bulls say / Bears say

Operating cash flow surged to $23.2 million in Q2 2026, up from $2.7 million in the prior year quarter, reflecting improved working capital management and freeing internal funds for growth initiatives. (SEC)
Gross margin expanded by 150 basis points to 85.5% year-over-year in Q2 2026, driven by a favorable mix shift toward the higher-margin Inspire V system, underpinning stronger profitability. (SEC)
Project Horizon is expected to generate approximately $30 million of annualized growth investment capacity through organizational streamlining and supply chain optimization, enabling the company to redeploy resources into high-return initiatives. (Investing.com)
Revenue fell 7.6% year-over-year to $200.6 million in Q2 2026, primarily driven by a U.S. sales decline amid evolving coding and reimbursement challenges, signaling continued domestic headwinds. (SEC)
The company reported a GAAP operating loss of $0.5 million and net earnings of only $0.3 million in Q2 2026, underscoring persistent profitability constraints despite cost reductions. (SEC)
Project Horizon will incur $20 million to $25 million of pre-tax restructuring charges in 2026, introducing execution risk and near-term expense volatility that could weigh on results. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.

INSP Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

INSP Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

INSP News

AllArticlesVideos

Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results

Benzinga1 month ago

Inspire Medical Systems Q2 Earnings Call Highlights

MarketBeat2 months ago

Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP

Business Wire2 months ago

Funds containing INSP

AllGBPUSDEUR
Funds
Fund name
Fund size
$INSP weighting
Xtrackers S&P 500 Swap£XSPX
£3.1B0.11%
iShares S&P SmallCap 600$IDP6
$3.2B0.11%
iShares S&P Small Cap 600£ISP6
£2.4B0.11%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.07%
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG
€2.8B0.04%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.